GlaxoSmithKline and the Biomedical Advanced Research and Development Authority, part of the U.S. government, signed a contract for anthrax treatment. Sheri Mullen, vice president of Immunology & Rare Diseases, U.S. Pharmaceuticals, GSK, said the four-year agreement calls for the provision of its inhalation anthrax treatment, raxibacumab. Read the full story